Aggressive NK-cell leukemia

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

6 events
Dec 2024JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialRECRUITING
Sep 2023Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Hiroshima University Hospital — PHASE1, PHASE2

TrialRECRUITING
May 2023Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

The Affiliated Hospital of Xuzhou Medical University — PHASE2

TrialRECRUITING
Sep 2022ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Abcuro, Inc. — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Aug 2021A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center — PHASE1

TrialRECRUITING
Aug 2013Registry of the German CLL Study Group

German CLL Study Group

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Aggressive NK-cell leukemia.
Check the disease page for updates →

Clinical Trial Landscape

3 active trials
2Phase 2
1PHASE1, PHASE2
3Total recruiting
Search clinical trials for Aggressive NK-cell leukemia

Recent News & Research

No recent news articles indexed yet for Aggressive NK-cell leukemia.
Search PubMed for Aggressive NK-cell leukemia

Browse all Aggressive NK-cell leukemia news →

Specialist Network

Top 6 by expertise

View all Aggressive NK-cell leukemia specialists →

Quick Actions